An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Conditions:   C3G;   IC-MPGN;   C3 Glomerulopathy;   C3 Glomerulonephritis;   Complement 3 Glomerulopathy;   Complement 3 Glomerulopathy (C3G);   Complement 3 Glomerulonephritis;   Dense Deposit Disease;   DDD;   Membranoproliferative Glomerulonephritis;   Membranoproliferative Glomerul onephritis (MPGN);   Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Intervention:   Drug: Pegcetacoplan Sponsor:   Apellis Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials